Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Ji Son(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Lauren Cobb(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Barrett C. Lawson(The University of Texas MD Anderson Cancer Center), Pablo Álvarez Ballesteros(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Amber M. Johnson(The University of Texas MD Anderson Cancer Center), Richard K. Yang(The University of Texas MD Anderson Cancer Center), Natalie Clark(The University of Texas MD Anderson Cancer Center), Amadeo B. Biter(The University of Texas MD Anderson Cancer Center), Yingao Zhang(Baylor College of Medicine), Oriol Mirallas(Hebron University), Heather Lin(The University of Texas MD Anderson Cancer Center), R. Tyler Hillman(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Mirella Nardo(The University of Texas MD Anderson Cancer Center), Elizabeth D. Euscher(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Vijaykumar Holla(The University of Texas MD Anderson Cancer Center), Erick Campbell(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882